ASCO 2017 | CLL: results of the phase II CALGB 10404 and phase III GENUINE trials, and a retrospective analysis of Richter’s Transformation with novel agents
At the 2017 ASCO Annual Meeting, an oral abstract session took place where 3 key oral...
Ublituximab and umbralisib for R/R B-cell NHL and CLL/SLL
Results of a phase I/Ib study (NCT02006485) to evaluate the safety and efficacy of U2, in patients with R/R B-cell NHL and CLL/SLL
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month